The main purpose of this legislation is to improve healthcare for individuals affected by per- and polyfluoroalkyl substances (PFAS), which are harmful chemicals often found in drinking water and various consumer products. The law aims to ensure that medical professionals have access to the most current clinical guidance on the health effects of PFAS exposure. Key provisions of the law include the establishment of an agreement between the Director of the Agency for Toxic Substances and Disease Registry and the National Academies of Sciences, Engineering, and Medicine.